In a strategic move, ANI Pharmaceuticals has put forward a US$560 million bid to take over Egetis Therapeutics, a Swedish biotech firm, thereby securing rights to Emcitate, the pioneering therapy for MCT8 deficiency. This New Jersey-based drugmaker unveiled its acquisition plans on Thursday, coinciding with its third-quarter financial report. Should the deal go through, Emcitate will join ANI’s lineup, bolstering its presence in the rare disease sector.
Strengthening Presence in Rare Diseases
Emcitate addresses a critical need among patients with limited treatment options. The medication gained European approval last winter and U.S. approval on September 28, marking the first therapy for MCT8 deficiency. This condition, impacting roughly one in 70,000 males globally and over 1,000 individuals in the U.S., hinders thyroid hormone absorption in brain cells, impairing neurological growth and physical movement.
ANI forecasts that Emcitate could reach up to US$300 million in annual sales at its peak. The drug’s U.S. launch occurred on October 27. Prior to the acquisition, Egetis had already engaged with major pharmacy benefit managers and over a third of state Medicaid programs. Chris Mutz, ANI’s rare disease lead, anticipates that the lack of competing treatments will aid in securing reimbursement from insurers and Medicaid. The disorder impedes thyroid hormone entry into brain cells, affecting cognitive function, mobility, and overall well-being.
Ensuring broad access to the treatment will be a key focus for the merged entity. ANI aims to leverage its existing commercial network to enhance availability. Additionally, the company stands to benefit from a rare pediatric disease priority review voucher granted after Emcitate’s FDA approval. This voucher is projected to yield US$190 million, effectively lowering the acquisition’s adjusted value to around US$434 million. Emcitate holds orphan drug status in both the U.S. and EU, with patent protection until 2045.
Financial Details and Transaction Terms
The offer values Egetis shares at SEK 11.25 each, equivalent to US$1.15, marking a 27% premium over the company’s 60-day average share price. Egetis’ board has unanimously endorsed the proposal, and shareholders holding 42% of the company’s stock have signaled their approval. However, ANI needs at least 90% shareholder consent to finalize the deal.
ANI’s third-quarter revenue climbed 27.6% year-over-year to US$290.8 million, surpassing market expectations. The company projects full-year revenue of approximately US$1.1 billion. In contrast, Egetis reported US$2.2 million in quarterly revenue and a net loss of US$14.3 million, with US$26.7 million in cash reserves at quarter’s end.
This acquisition marks another step in ANI’s growth trajectory. The company acquired Alimera Sciences for over US$380 million in 2024 and Novitium for US$163 million in 2021, in addition to purchasing generic and branded drugs from various manufacturers. The deal will also enhance ANI’s research efforts. Egetis is conducting preclinical studies to explore Emcitate’s potential in treating resistance to thyroid hormone beta (RTH-beta), another rare thyroid disorder. The acceptance window for the offer is set to open in late November and run through December.
Leave a Reply